LaingBuisson News
Sander Slootweg, managing partner and co-founder of Forbion
European life sciences venture capital firm, Forbion, has announced the final close of its Forbion Growth 1 Fund at â¬360m (US$428m). The fund is focused on investing in late-stage life sciences companies, particularly European companies that develop novel therapies for areas of high medical need. The hard cap exceeds the original target size of â¬250m.
Forbion uses three strategies that aim to provide: private growth capital for clinical stage development assets, cross-over capital to companies aiming to pursue a public listing in the near-term, as well as capital injections that support existing under-valued public companies. It plans to take a leading position in its targets with an investment size of up to â¬35m per deal.